Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, pneumonia, mechanical ventilation, and respiratory failure in infants in the US. No effective post-infection treatments are widely available, and currently there is no vaccine. RSV disease is the result of virus-induced airway damage and complex inflammatory processes. The outcome of infection depends on host and viral genetics. Here, we review disease mechanisms in primary RSV infection that are implicated by clinical studies, in vitro systems, and animal models. Defining RSV disease mechanisms is difficult because there is a wide range of RSV disease phenotypes in humans, and there are disparities in RSV disease phenotypes among the animal models of RSV infection. However, host factors identified by multiple lines of investigation as playing important roles in RSV pathogenesis are providing key insights. A better understanding of RSV molecular biology and RSV pathogenesis is facilitating rational vaccine design strategies and molecular targets for new therapeutics.
Moore
Martin L
ML
Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, T-1218 MCN, Vanderbilt University School of Medicine, Nashville, TN 37232-2650, USA.
Peebles
R Stokes
RS
D000818:Animals; D016207:Cytokines; D006801:Humans; D051379:Mice; D010641:Phenotype; D051381:Rats; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes
D016207:Cytokines; D022261:Respiratory Syncytial Virus Vaccines